Navegando por Autor "ANDRADE, Luis Eduardo Coelho"

Agora exibindo 1 - 3 de 3

Acesso aberto (Open Access)
3º Consenso Brasileiro para pesquisa de autoanticorpos em células HEp-2 (FAN): recomendações para padronização do ensaio de pesquisa de autoanticorpos em células HEp-2, controle de qualidade e associações clínicas
(2009-04) DELLAVANCE, Alessandra; GABRIEL JÚNIOR, Alexandre; NUCCITELLI, Barbara; TALIBERTI, Ben-Hur Braga; VON MÜHLEN, Carlos Alberto; BICHARA, Carlos David Araújo; SANTOS, Cláudio Henrique Ramos dos; BUENO, Cleonice; YANO, Cristiane Martinez; MANGUEIRA, Cristóvão Luis Pitangueira; CARVALHO, Darlene Gonçalves; CARDOSO, Elizângela; BONFÁ, Eloísa Silva Dutra de Oliveira; ARAÚJO, Flávia Ikeda e; RASSI, Gustavo Gabriel; MUNDIM, Hugo Mendonça; BENDET, Izidro; RÊGO, Jozelia; VIEIRA, Lisiane Maria Enriconi dos Anjos; ANDRADE, Luis Eduardo Coelho; BARBOSA, Maria Ordália Ferro; SUGIYAMA, Mitiko; SANTIAGO, Mittermayer Barreto; BARRETO, Natasha Slhessarenko Fraife; SILVA, Nilzio Antônio da; FRANCESCANTONIO, Paulo Luiz Carvalho; JARACH, Renata; SUDA, Roberto; LEVY, Roger Abramino; SAMPAIO, Silvia Oliveira; NEVES, Suzane Pretti Figueiredo; CRUVINEL, Wilson de Melo; SANTOS, Wilton Silva dos; NÓBREGA, Yanna Karla de Medeiros
The Third Brazilian Consensus for autoantibodies Screening in HEp-2 cells had as purpose the evaluation of difficulties in the accomplishment of the 2nd Consensus recommendations that took place in the year of 2002, the discussion of strategies for quality control of the assay and the promotion of an update of the clinical associations of the several immunofluorescent patterns. METHODS:Several ANA experts from university centers and private laboratories in different areas in Brazil joined the workshop in Goiânia on 2008 April 13 and 14 with the purpose of discussing and approving the recommendations for standardization, interpretation and use of the test by physicians. Commercial representatives of different ANA slide brands were also invited as listeners to the workshop. RESULTS AND CONCLUSIONS: The 3rd Consensus emphasized the need for quality control in indirect immunofluorescent since there is a considerable heterogeneity of available microscopes and reagents. It also promoted adaptations in the previously approved terminology used to classify the different patterns and finally updated the clinical associations of the several patterns with the purpose of providing guidance for interpretation of the assay by clinical pathologists and assistant physicians.
Acesso aberto (Open Access)
III Consenso Brasileiro para Pesquisa de Autoanticorpos em Células HEp-2: perspectiva histórica, controle de qualidade e associações clínicas
(2009-06) FRANCESCANTONIO, Paulo Luiz Carvalho; ANDRADE, Luis Eduardo Coelho; CRUVINEL, Wilson de Melo; ARAÚJO, Flávia Ikeda e; DELLAVANCE, Alessandra; GABRIEL JÚNIOR, Alexandre; NUCCITELLI, Barbara; TALIBERTI, Ben-Hur Braga; VON MÜHLEN, Carlos Alberto; BICHARA, Carlos David Araújo; SANTOS, Cláudio Henrique Ramos dos; BUENO, Cleonice; YANO, Cristiane Martinez; MANGUEIRA, Cristóvão Luis Pitangueira; CARVALHO, Darlene Gonçalves; CARDOSO, Elizângela; BONFÁ, Eloísa Silva Dutra de Oliveira; RASSI, Gustavo Gabriel; MUNDIM, Hugo Mendonça; BENDET, Izidro; RÊGO, Jozelia; VIEIRA, Lisiane Maria Enriconi dos Anjos; BARBOSA, Maria Ordália Ferro; SUGIYAMA, Mitiko; SANTIAGO, Mittermayer Barreto; BARRETO, Natasha Slhessarenko Fraife; SILVA, Nilzio Antônio da; JARACH, Renata; SUDA, Roberto; LEVY, Roger Abramino; SAMPAIO, Silvia Oliveira; NEVES, Suzane Pretti Figueiredo; SANTOS, Wilton Silva dos; NÓBREGA, Yanna Karla de Medeiros
OBJECTIVE: The Third Brazilian Consensus for Autoantibodies Screening in HEp-2 Cells (ANA) had as purpose the evaluation of difficulties in the accomplishment of the 2nd Consensus recommendations that took place in the year of 2002, the discussion of strategies for quality control of the assay and the discussion of an update of the clinical associations of the several immunofluorescent patterns. METHODS: Several ANA experts from university centers and private laboratories in different areas in Brazil joined the workshop in Goiânia on 2007 April 13 and 14 with the purpose of discussing and approving the recommendations for standardization, interpretation and use of the test by physicians. Commercial representatives of different ANA slide brands were also invited as listeners to the workshop. RESULTS AND CONCLUSION: The 3rd ANA Consensus emphasized the need for quality control in indirect immunofluorescent assays since there is a considerable heterogeneity of available microscopes and reagents. It also promoted adaptations in the previously approved terminology used to classify the different patterns and finally updated the clinical associations of the several patterns with the purpose of providing guidance for interpretation of the assay by clinical pathologists and assistant physicians.
Acesso aberto (Open Access)
IL-2, IL-5, TNF-α and IFN-γ mRNA expression in epidermal keratinocytes of systemic lupus erythematosus skin lesions
(2011) CARNEIRO, José Ronaldo Matos; FUZII, Hellen Thais; KAYSER, Cristiane; ALBERTO, Fernando Lopes; SOARES, Fernando Augusto; SATO, Emília Inoue; ANDRADE, Luis Eduardo Coelho
OBJECTIVE: To analyze cytokine gene expression in keratinocytes from patients with systemic lupus erythematosus (SLE). INTRODUCTION: Keratinocytes represent 95% of epidermal cells and can secrete several cytokines. METHODS: Keratinocytes were obtained by laser microdissection from 21 patients with SLE (10 discoid and 11 acute lesions) at involved and uninvolved sites. All patients were receiving a low/moderate prednisone dose and 18 were receiving chloroquine diphosphate. IL-2, IL-5, TNF-α and IFN-γ gene expression was evaluated by real-time PCR and expressed as the ratio (R) to a pool of skin samples from 12 healthy volunteers. RESULTS: Heterogeneity in cytokine gene expression was found among patients with SLE. Eighteen of 38 valid SLE samples (47%) presented overexpression (R>1) of at least one cytokine. Lesional skin samples tended to show higher cytokine expression than samples from uninvolved skin (p = 0.06). IL-5 and IFN-γ were the most commonly overexpressed cytokines. Samples with cytokine overexpression corresponded to more extensive and severe lesions. Prednisone dose did not differ between samples without cytokine overexpression (15.71±3.45 mg/day) and those with overexpressed cytokines (12.68±5.41 mg/day) (p = 0.216). Samples from all patients not receiving diphosphate chloroquine had at least one overexpressed cytokine. CONCLUSIONS: The heterogeneous keratinocyte cytokine gene expression reflects the complex immunological and inflammatory background in SLE. Patients with severe/extensive skin lesions showed a higher frequency of cytokine gene overexpression. Increased IFN-γ and IL-5 expression suggests that Th1 and Th2 cells are involved in SLE skin inflammation. The possibility that prednisone and antimalarial drugs may have contributed to low cytokine gene expression in some samples cannot be ruled out.